JP2025510606A5 - - Google Patents
Info
- Publication number
- JP2025510606A5 JP2025510606A5 JP2024554214A JP2024554214A JP2025510606A5 JP 2025510606 A5 JP2025510606 A5 JP 2025510606A5 JP 2024554214 A JP2024554214 A JP 2024554214A JP 2024554214 A JP2024554214 A JP 2024554214A JP 2025510606 A5 JP2025510606 A5 JP 2025510606A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- pharmaceutically acceptable
- conjugate according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210334522 | 2022-03-30 | ||
| CN202210334522.X | 2022-03-30 | ||
| PCT/CN2023/085097 WO2023186015A1 (zh) | 2022-03-30 | 2023-03-30 | B7h4抗体药物偶联物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510606A JP2025510606A (ja) | 2025-04-15 |
| JP2025510606A5 true JP2025510606A5 (https=) | 2026-04-01 |
Family
ID=88199403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554214A Pending JP2025510606A (ja) | 2022-03-30 | 2023-03-30 | Ｂ７ｈ４抗体薬物複合体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250032630A1 (https=) |
| EP (1) | EP4501363A1 (https=) |
| JP (1) | JP2025510606A (https=) |
| KR (1) | KR20240163098A (https=) |
| CN (1) | CN118922210A (https=) |
| AU (1) | AU2023245347A1 (https=) |
| CA (1) | CA3245849A1 (https=) |
| CL (1) | CL2024002903A1 (https=) |
| CO (1) | CO2024013243A2 (https=) |
| IL (1) | IL315698A (https=) |
| MX (1) | MX2024011866A (https=) |
| TW (2) | TW202448955A (https=) |
| WO (1) | WO2023186015A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024078449A1 (en) * | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
| WO2024098066A1 (en) * | 2022-11-04 | 2024-05-10 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| TW202529816A (zh) * | 2023-10-14 | 2025-08-01 | 大陸商上海翰森生物醫藥科技有限公司 | 癌症的抗體藥物偶聯物療法 |
| TW202535883A (zh) * | 2023-10-23 | 2025-09-16 | 美商翰森生物有限責任公司 | 配體–細胞毒性藥物偶聯物及其藥物用途 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2025241867A1 (zh) * | 2024-05-24 | 2025-11-27 | 明慧医药（杭州）有限公司 | 抗b7-h4抗体药物偶联物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| WO2016040724A1 (en) * | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| CN116693686A (zh) * | 2018-02-11 | 2023-09-05 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| US20230072897A1 (en) * | 2019-06-06 | 2023-03-09 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-b7-h4 antibody-drug conjugate and medicinal use thereof |
| JP7726534B2 (ja) * | 2020-06-30 | 2025-08-20 | 諾納生物（蘇州）有限公司 | 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途 |
-
2023
- 2023-03-30 KR KR1020247033188A patent/KR20240163098A/ko active Pending
- 2023-03-30 CA CA3245849A patent/CA3245849A1/en active Pending
- 2023-03-30 JP JP2024554214A patent/JP2025510606A/ja active Pending
- 2023-03-30 EP EP23778380.8A patent/EP4501363A1/en active Pending
- 2023-03-30 WO PCT/CN2023/085097 patent/WO2023186015A1/zh not_active Ceased
- 2023-03-30 IL IL315698A patent/IL315698A/en unknown
- 2023-03-30 TW TW113121305A patent/TW202448955A/zh unknown
- 2023-03-30 CN CN202380030107.8A patent/CN118922210A/zh active Pending
- 2023-03-30 TW TW112112350A patent/TW202340255A/zh unknown
- 2023-03-30 AU AU2023245347A patent/AU2023245347A1/en active Pending
-
2024
- 2024-09-26 MX MX2024011866A patent/MX2024011866A/es unknown
- 2024-09-27 CL CL2024002903A patent/CL2024002903A1/es unknown
- 2024-09-27 US US18/900,491 patent/US20250032630A1/en active Pending
- 2024-09-30 CO CONC2024/0013243A patent/CO2024013243A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510606A5 (https=) | ||
| JP2024535637A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| US8889130B2 (en) | Treatment of osteoarthritis and pain | |
| JP2019031565A5 (https=) | ||
| JP2023535598A5 (https=) | ||
| JP2025503214A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| EP3678700B1 (en) | Compounds for reducing the viscosity of biological formulations | |
| JP2014139173A5 (https=) | ||
| RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2021527640A5 (https=) | ||
| JP2022507781A5 (https=) | ||
| JP2023504187A5 (https=) | ||
| JP2025503214A (ja) | Ｈｅｒ３抗体－薬物結合体及びその使用 | |
| JP2018123122A5 (https=) | ||
| JP2020534326A5 (https=) | ||
| EP4525930A1 (en) | Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates | |
| JP2025508779A5 (https=) | ||
| AU2022316425A1 (en) | Drug conjugate of eribulin derivative | |
| JPWO2023033129A5 (https=) | ||
| JP2023552790A5 (https=) | ||
| RU2025131232A (ru) | Конъюгат антитело анти-cdh6-лекарственное средство и его применение | |
| RU2025113325A (ru) | Конъюгат антитело-лекарственное средство, включающий анти-клаудин-18.2 антитело, и его применение в терапии рака | |
| RU2023134008A (ru) | Применение конъюгата, нацеленное на her2 антитело - лекарственное средство, в лечении рака молочной железы с низкой экспрессией her2 |